Literature DB >> 27226545

Characterization of the Regulation of CD46 RNA Alternative Splicing.

Sze Jing Tang1, Shufang Luo1, Jia Xin Jessie Ho1, Phuong Thao Ly1, Eling Goh1, Xavier Roca2.   

Abstract

Here we present a detailed analysis of the alternative splicing regulation of human CD46, which generates different isoforms with distinct functions. CD46 is a ubiquitous membrane protein that protects host cells from complement and plays other roles in immunity, autophagy, and cell adhesion. CD46 deficiency causes an autoimmune disorder, and this protein is also involved in pathogen infection and cancer. Before this study, the mechanisms of CD46 alternative splicing remained unexplored even though dysregulation of this process has been associated with autoimmune diseases. We proved that the 5' splice sites of CD46 cassette exons 7 and 8 encoding extracellular domains are defined by noncanonical mechanisms of base pairing to U1 small nuclear RNA. Next we characterized the regulation of CD46 cassette exon 13, whose inclusion or skipping generates different cytoplasmic tails with distinct functions. Using splicing minigenes, we identified multiple exonic and intronic splicing enhancers and silencers that regulate exon 13 inclusion via trans-acting splicing factors like PTBP1 and TIAL1. Interestingly, a common splicing activator such as SRSF1 appears to repress CD46 exon 13 inclusion. We also report that expression of CD46 mRNA isoforms is further regulated by non-sense-mediated mRNA decay and transcription speed. Finally, we successfully manipulated CD46 exon 13 inclusion using antisense oligonucleotides, opening up opportunities for functional studies of the isoforms as well as for therapeutics for autoimmune diseases. This study provides insight into CD46 alternative splicing regulation with implications for its function in the immune system and for genetic disease.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  alternative splicing; complement system; exonic splicing enhancer; exonic splicing silencer; lymphocyte; molecular genetics

Mesh:

Substances:

Year:  2016        PMID: 27226545      PMCID: PMC4933185          DOI: 10.1074/jbc.M115.710350

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  86 in total

1.  TIA-1 and TIAR activate splicing of alternative exons with weak 5' splice sites followed by a U-rich stretch on their own pre-mRNAs.

Authors:  C Le Guiner; F Lejeune; D Galiana; L Kister; R Breathnach; J Stévenin; F Del Gatto-Konczak
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

2.  miRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3'UTR of CD46.

Authors:  Wenjing Cui; Yiwen Zhang; Nan Hu; Changliang Shan; Shuai Zhang; Weiying Zhang; Xiaodong Zhang; Lihong Ye
Journal:  Cancer Biol Ther       Date:  2010-08-07       Impact factor: 4.742

3.  The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing.

Authors:  Eugene V Makeyev; Jiangwen Zhang; Monica A Carrasco; Tom Maniatis
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

4.  Widespread recognition of 5' splice sites by noncanonical base-pairing to U1 snRNA involving bulged nucleotides.

Authors:  Xavier Roca; Martin Akerman; Hans Gaus; Andrés Berdeja; C Frank Bennett; Adrian R Krainer
Journal:  Genes Dev       Date:  2012-05-15       Impact factor: 11.361

5.  Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing.

Authors:  R W Johnstone; S M Russell; B E Loveland; I F McKenzie
Journal:  Mol Immunol       Date:  1993-10       Impact factor: 4.407

6.  SRSF1-Regulated Alternative Splicing in Breast Cancer.

Authors:  Olga Anczuków; Martin Akerman; Antoine Cléry; Jie Wu; Chen Shen; Nitin H Shirole; Amanda Raimer; Shuying Sun; Mads A Jensen; Yimin Hua; Frédéric H-T Allain; Adrian R Krainer
Journal:  Mol Cell       Date:  2015-10-01       Impact factor: 17.970

Review 7.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

Authors:  Z Fishelson; N Donin; S Zell; S Schultz; M Kirschfink
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

8.  Characterization of human membrane cofactor protein (MCP; CD46) on spermatozoa.

Authors:  Rebecca C Riley; Claudia Kemper; Marilyn Leung; John P Atkinson
Journal:  Mol Reprod Dev       Date:  2002-08       Impact factor: 2.609

9.  Recognition of atypical 5' splice sites by shifted base-pairing to U1 snRNA.

Authors:  Xavier Roca; Adrian R Krainer
Journal:  Nat Struct Mol Biol       Date:  2009-01-25       Impact factor: 15.369

Review 10.  Pick one, but be quick: 5' splice sites and the problems of too many choices.

Authors:  Xavier Roca; Adrian R Krainer; Ian C Eperon
Journal:  Genes Dev       Date:  2013-01-15       Impact factor: 11.361

View more
  14 in total

Review 1.  Complement and the Regulation of T Cell Responses.

Authors:  Erin E West; Martin Kolev; Claudia Kemper
Journal:  Annu Rev Immunol       Date:  2018-04-26       Impact factor: 28.527

2.  SRRM2 organizes splicing condensates to regulate alternative splicing.

Authors:  Shaohai Xu; Soak-Kuan Lai; Donald Yuhui Sim; Warren Shou Leong Ang; Hoi Yeung Li; Xavier Roca
Journal:  Nucleic Acids Res       Date:  2022-08-26       Impact factor: 19.160

3.  Ex Vivo and In Vivo CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26).

Authors:  Jack R Hemsath; A Manuel Liaci; Jeffrey D Rubin; Brian J Parrett; Shao-Chia Lu; Tien V Nguyen; Mallory A Turner; Christopher Y Chen; Karolina Cupelli; Vijay S Reddy; Thilo Stehle; M Kathryn Liszewski; John P Atkinson; Michael A Barry
Journal:  J Virol       Date:  2021-11-17       Impact factor: 6.549

4.  Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

Authors:  Sarah E Sartain; Nancy A Turner; Joel L Moake
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

Review 5.  Roles of PTBP1 in alternative splicing, glycolysis, and oncogensis.

Authors:  Wei Zhu; Bo-Lun Zhou; Li-Juan Rong; Li Ye; Hong-Juan Xu; Yao Zhou; Xue-Jun Yan; Wei-Dong Liu; Bin Zhu; Lei Wang; Xing-Jun Jiang; Cai-Ping Ren
Journal:  J Zhejiang Univ Sci B       Date:  2020-02-05       Impact factor: 3.066

Review 6.  The RNA binding protein SRSF1 is a master switch of gene expression and regulation in the immune system.

Authors:  Sean Paz; Anastasia Ritchie; Christopher Mauer; Massimo Caputi
Journal:  Cytokine Growth Factor Rev       Date:  2020-11-02       Impact factor: 7.638

7.  Non-random pairing of CD46 isoforms with skewing towards BC2 and C2 in activated and memory/effector T cells.

Authors:  Aida S Hansen; Bettina B Bundgaard; Bjarne K Møller; Per Höllsberg
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

Review 8.  Complement as a regulator of adaptive immunity.

Authors:  Justin Killick; Gregoire Morisse; Dirk Sieger; Anne L Astier
Journal:  Semin Immunopathol       Date:  2017-08-25       Impact factor: 9.623

9.  Blocking the 5' splice site of exon 4 by a morpholino oligomer triggers APOL1 protein isoform switch.

Authors:  Amber M Cheatham; Shamara E Davis; Atanu K Khatua; Waldemar Popik
Journal:  Sci Rep       Date:  2018-06-07       Impact factor: 4.379

10.  Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides.

Authors:  Jun Liu; Malini Bhadra; Joanna Rajeswary Sinnakannu; Wan Lin Yue; Cheryl Weiqi Tan; Frank Rigo; S Tiong Ong; Xavier Roca
Journal:  Oncotarget       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.